# Semaglutide: The GLP-1 Peptide and the Trial Record, Charted > Semaglutide drove a mean 14.9% body-weight drop over 68 weeks in the STEP 1 trial. A forward-looking, cited digest of the GLP-1 chemistry, the weight-management evidence, and the safety record. A forward-looking digest of the GLP-1 chemistry, the weight-management evidence, and the open questions, with every number plotted to the study that produced it. ## The short version Semaglutide is a lab-built copy of a natural gut hormone called GLP-1, the signal your body sends after a meal that says "you've eaten enough." Chemists rebuilt that small protein so it survives in the blood for about a week instead of a couple of minutes, which is why one weekly dose works. It does three things: it nudges the pancreas to release insulin when blood sugar is high, it slows how fast the stomach empties, and — the part most people care about — it reaches the brain's appetite control center and quiets hunger. In the large STEP 1 study, adults on it lost about 14.9% of their body weight over roughly 16 months, versus 2.4% on a placebo [1]. It is an approved medicine, not an experiment. The catch: stomach side effects are common early on, and what people report — including the downsides — is on [the effects page](/effects). ## What the semaglutide literature has demonstrated Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a drug that switches on the same receptor as the body's own incretin hormone (a gut signal released after eating that tells the pancreas to make insulin and tells the brain you are full) [4]. Across the phase-3 record the results have been large and repeatable. In STEP 1, once-weekly subcutaneous (under-the-skin) semaglutide at the 2.4 mg dose produced a mean body-weight change of -14.9% from baseline to week 68, against -2.4% on placebo — a roughly 12.4 percentage-point gap [1]. The story does not stop at the scale. In SUSTAIN-6, the drug cut the combined rate of cardiovascular death, nonfatal heart attack and nonfatal stroke in people with type 2 diabetes (hazard ratio 0.74; 95% CI 0.58-0.95) [2]. In SELECT — 17,604 adults with heart disease and obesity but no diabetes — the 2.4 mg dose lowered those same major cardiovascular events by 20% (HR 0.80; 95% CI 0.72-0.90) [3]. In FLOW, it reduced major kidney-disease events in diabetic chronic kidney disease by 24% (HR 0.76) [6]. This is [Semaglutide research](/research) measured across organ systems, not a single endpoint. ## A peptide engineered for the long haul The chemistry is the quiet headline. Native GLP-1 is destroyed within about two minutes by an enzyme called DPP-4 (dipeptidyl peptidase-4, a protein-cutting enzyme in the blood). Semaglutide swaps one building block at position 8 for a non-natural amino acid (Aib, alpha-aminoisobutyric acid) that blocks that cut, and bolts on a C18 fatty-acid tail that clips reversibly onto albumin — the most abundant carrier protein in blood. Riding on albumin keeps the peptide out of the kidney's filter, stretching its half-life to about one week [20]. That single design choice is what makes a weekly injection — and a daily pill — possible. The molecular formula is `C187H291N45O59`; the molecule weighs about 4,114 daltons. The weight-loss effect is mostly run from the brain. Rodent work mapped semaglutide reaching the brainstem and the hypothalamic arcuate nucleus — the appetite control hub — where it switches on the neurons that signal fullness and switches off the ones that drive hunger, cutting food intake without lowering how many calories the body burns [4]. ## An approved medicine, charted as literature This site treats semaglutide the way an observatory treats the sky: as a record worth plotting carefully. It is FDA-approved across several indications and two formulations — a once-weekly injection and a once-daily tablet — covering type 2 diabetes, chronic weight management, cardiovascular risk reduction in established heart disease, and, since 2025, a form of fatty-liver disease called MASH [20]. The point here is not to sell it or prescribe it; it is to read the trials in plain language and show their numbers next to their sources. Start wherever your curiosity points. The mechanism and the landmark studies live on the [Semaglutide research](/research) page. The dose schedules studied in trials and on the label are on the [dosage](/dosage) page. The honest account of benefits, side effects and cautions — including what real users describe — is on the [Semaglutide effects](/effects) page. And the head-to-head against the dual agonist tirzepatide is charted on both [/research](/research#semaglutide-vs-tirzepatide) and [/weight-loss](/weight-loss). --- A deep-space reading room for the semaglutide literature — the GLP-1 chemistry charted first and the STEP, SUSTAIN, SELECT and FLOW figures plotted to the studies that measured them, the boxed thyroid warning and the still-unconfirmed signals kept in plain view, and the community reports pinned to one side as anecdote; an observatory for an approved medicine, not a clinic, a prescriber, or a vendor.